Virax Biolabs Group Limited Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Subsequent Events

Subsequent Events	12 Months Ended
Mar. 31, 2025
Disclosure of non-adjusting events after reporting period [abstract]
Subsequent Events	Note 17 — Subsequent Events On April 8, 2025 the Company granted 214,500 stock options to certain employees and directors with an exercise price of $0.88 and a three year vesting period. On June 13, 2025, 157,250 stock options that were granted to the former Chief Financial Officer were forfeited due to his resignation on that same date. There is a 90 day period to exercise 61,500 of these stock options.

Subsequent Events

12 Months Ended

Mar. 31, 2025

Disclosure of non-adjusting events after reporting period [abstract]

Subsequent Events

Note 17 — Subsequent Events

On April 8, 2025 the Company granted 214,500 stock options to certain employees and directors with an exercise price of $0.88 and a three year vesting period. On June 13, 2025, 157,250 stock options that were granted to the former Chief Financial Officer were forfeited due to his resignation on that same date. There is a 90 day period to exercise 61,500 of these stock options.